Cancer Therapy: AOP Health Investigates a New Approach Targeting Cancer Stem Cells

VIENNA -- AOP Orphan Pharmaceuticals GmbH (AOP Health) in collaboration with Leukos Biotech has achieved a key milestone. The first patient was included in the phase I clinical trial SERONCO-1, in which a substance with a new and unique mechanism of action (first-in-class) is being investigated. The drug candidate is being studied in patients with solid tumors and lymphomas. This development program builds on AOP Health’s proven success in delivering cancer stem cell targeting agents that address patients’ unmet medical needs. Read More

Cancer Therapy: AOP Health Investigates a New Approach Targeting Cancer Stem Cells

Cancer Therapy: AOP Health Investigates a New Approach Targeting Cancer Stem Cells

Cancer Therapy: AOP Health Investigates a New Approach Targeting Cancer Stem Cells

Cancer Therapy: AOP Health Investigates a New Approach Targeting Cancer Stem Cells

Cancer Therapy: AOP Health Investigates a New Approach Targeting Cancer Stem Cells